Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus DOXY 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus DOXY 100.
ACTICLATE CAP vs DOXY 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic